Conference Coverage
Latest News
Advertisement
Shorts
0:37
Andreas Pollreisz, MD, encourages taking a second look with OCT-A
a month ago
by
Andreas Pollreisz, MD(+1 more)
0:43
Sofia Androudi on retinal disorders mimicking inherited retinal diseases
a month ago
by
Sofia Androudi, MD(+1 more)
0:43
Elon van Dijk on central serous chorioretinopathy
a month ago
by
Elon van Dijk(+1 more)
0:50
Timothy Lai discusses the SALWEEN 1-year data
a month ago
by
Timothy Lai(+2 more)
0:37
Giuseppe Querques, MD, PhD, sheds light on two challenging pathophysiologies at EURETINA
a month ago
by
Giuseppe Querques, MD, PhD(+1 more)
0:49
Why the current staging for diabetic eye disease is obsolete
a month ago
by
Stela Vujosevic, MD, PhD, FEBO(+2 more)
Podcasts
Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME
Behind the scenes of building impactful educational platforms in retina care
The Retina TL;DR: Rethinking retinal detachment repair with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD
In the debut episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD, about PYK-2101, a biodegradable retinal sealant designed to replace gas and oil tamponades.
PHOTON Trial Outcomes: Impact on DME Patient Care in Clinical Practice
John Kitchens, MD, and Diana Do, MD, delve into the PHOTON trial results and their significance for treating patients with diabetic macular edema in clinical settings.
PULSAR Study Findings: Implications for Treating nAMD in Clinical Practice
Join John Kitchens, MD, and David Brown, MD, as they explore the PULSAR study results and their impact on managing neovascular age-related macular degeneration in your practice.
Integrating AI to manage DR in a primary care setting
Ehsan Rahimy, MD, speaks on the highlights of a study he presented at this year's virtual AAO 2020 meeting that aimed to integrate an artificial intelligence screening system for managing diabetic retinopathy referrals in a primary care setting — with limited specialty support.
What to expect from virtual AAO 2020
American Academy of Ophthalmology (AAO) President Anne L. Coleman, MD, PhD, offers a preview of what attendees can look forward to from the academy's 2020 virtual annual meeting — kicking off Nov. 13-15.
Spotlighting telemedicine in the year of a pandemic
In this EyePod episode, Ranya Habash, MD, of Bascom Palmer Eye Institute, University of Miami, speaks on the expansion of telemedicine in ophthalmology amid the pandemic and why the future of telemedicine requires a new way of thinking.
Putting in practice retina innovations amid a pandemic
S.K. Steven Houston III, MD, shares how his practice has put to use recent retina innovations and adapted to accommodate the ever-changing operating room spacing and set-up in the current COVID-19 environment.
ASRS 2020: Evaluating 3-year-recurrence rate in non-infectious posterior segment uveitis post-FAi
Dilraj Grewal, MD, associate professor of ophthalmology at Duke Eye Center/ director of grading at the Duke Reading Center, speaks on his presentation "Evaluating the True 3-Year Recurrence Rate in Non-infectious Posterior Segment Uveitis Following an Injectable Fluocinolone Acetonide Insert," during the virtual 2020 ASRS meeting.
Videos
Modern Retina Digital Edition
Revisiting a classic tool that still gets you out of a jam works best when you understand its powers and limitations.
Reliable visualization tools, especially those indicated for ocular use, are crucial for success.
A look at podium presentations on GA research at ASRS 2025.
Catch up on recent advancements in retina care, including new therapies for age-related macular degeneration and macular telangiectasia, enhancing patient outcomes.
The role of anesthetics in streamlining efficiency and elevating patient care.
Patients weigh in on the value of provider communication.
How artificial intelligence could enhance clinical trials.
Research from the iMIND lab at Duke University.
Retinal imaging and the future of early Alzheimer diagnosis.
Continuing Medical Education
Advertisement
All News
Advertisement
The EURETINA meeting featured new treatments in gene therapy and innovative implants to enhance patient quality of life.
David R. Lally, MD, discusses promising results from the ARCHER trial on ANX007 for age-related macular degeneration, emphasizing the need for vision-preserving treatments.
Learn how the YOURS Committee empowers young retina specialists through engaging educational initiatives, networking opportunities, and exam preparation resources.
Dr. Kristina Pfau discusses her research on pseudoxanthoma elasticum and the initiatives of EURETINA's Young Ophthalmologist and Retina Specialists Committee.
Catch up on this week's highlights in retina.
Eydenzelt is Celltrion's first FDA-approved biologic product in ophthalmology.
Biomarkers and fine-tuned staging are key to progress in improving retinal care, according to Fanka Gilevska, MD, PhD.
Ultra-high-resolution OCT advances retinal imaging, enabling detailed visualization of disease progression and potential therapeutic effects in eye conditions.
The Phase 1/2 ArMaDa trial is evaluating OCU410 (Ocugen), a gene therapy candidate for patients with dry age-related macular degeneration.
Advertisement
Sura-vec is intended to be a potential 1-time treatment consisting of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF).
Merck and EyeBio launch a pivotal trial for MK-3000, targeting diabetic macular edema with new treatment options to enhance patient outcomes.
The company can now initiate the Opti-GAIN (Optimized Geographic Atrophy INterventional) phase 1/2 clinical trial.
Additionally, the company also received Clinical Trial Authorization (CTA) approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).
NPI-001 is Nacuity’s investigational therapy for the treatment of patients with retinitis pigmentosa (RP).
Patient response focused on perceived vision-related quality of life outcomes, investigators said.
Catch up on this week's highlights in retina.
The Eye Care Network spoke with Sebastian Wolf, MD, PhD, and Sophie Bonnin, MD, PhD, who presented new findings from the OCS-05 phase 2 ACUITY trial.
Behind the scenes of building impactful educational platforms in retina care
The trial results show promising for the evaluated gene therapy for the treatments of LCA, showing significant vision improvements in pediatric patients.
The characteristics of these inherited retinal diseases make it difficult to define objective, clinically meaningful outcomes that are sensitive enough to measure change over the course of a trial.
Broadwood Partners, who is against the merger, holds approximately 27.5% of the outstanding common stock of STAAR, making them the largest outside stockholder of STAAR.
Christine Kay, MD, presents new findings on MCO-010, a novel optogenetic therapy improving vision in retinitis pigmentosa patients at the Retina Society meeting.
Hear highlights from the Vit-Buckle Society and its presence at EURETINA 2025.
Catch up on this week's highlights in retina.
ISTH0036 demonstrates potential to prevent fibrosis, reduce retinal fluid, and improve vision in AMD and diabetic macular edema patients.
The newly approved technology delivers low-dose microcurrents through closed eyelids to stimulate retinal cells.
EURETINA's 25th anniversary meeting attracts 11,000 participants, showcasing cutting-edge research and fostering global networking among retina specialists.
Advertisement
Advertisement
